Redeye comments on Alligator presenting new data on mitazalimab at SITC 40th Anniversary Annual Meeting last week. The abstract included data from the OPTIMIZE-1 trial in metastatic pancreatic cancer, indicating that the 900μg/kg dose showed numerically better efficacy compared to the 450mg dose. At six months, progression-free survival (PFS) was 50.8% for the 900μg/kg cohort, compared to 38.7% for the 450μg/kg cohort. Regarding overall survival (OS), the figures were 89.5% and 69.4%, respectively. The strong results further characterise efficacy and safety at the two dose levels.
LÄS MER
